• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Cytosorbents Corporation

    11/14/24 4:48:32 PM ET
    $CTSO
    Medical/Dental Instruments
    Health Care
    Get the next $CTSO alert in real time by email
    SC 13G/A 1 fp0090935-9_sc13ga.htm

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(b)

     

    (AMENDMENT NO. 1)*

     

    Cytosorbents Corporation

     

    (Name of Issuer)

     

    Common Stock, par value $0.001

     

    (Title of Class of Securities)

     

    23283X206

     

    (CUSIP Number)

     

    September 30, 2024

     

    (Date of Event Which Requires Filing of This Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [x]Rule 13d-1(b)
    [  ]Rule 13d-1(c)
    [  ]Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    CUSIP NO. 23283X206

    13G Page 2 of 5 Pages

     

    1

    NAMES OF REPORTING PERSONS S.S. OR
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS

     

    Granahan Investment Management LLC

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a) [  ]

    (b) [  ]

    3

    SEC USE ONLY

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    State of Massachusetts

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5

    SOLE VOTING POWER

     

    1,650,047

     
    6

    SHARED VOTING POWER

     

    None

     
    7

    SOLE DISPOSITIVE POWER

     

    2,094,882

     
    8

    SHARED DISPOSITIVE POWER

     

    None

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,094,882

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES

     

    [  ]

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    3.85%

     
    12

    TYPE OF REPORTING PERSON

     

    IA

     

     

     

    CUSIP NO. 23283X206 13G Page 3 of 5 Pages

     

    Item 1.(a) Name of Issuer:

     

    Cytosorbents Corporation

     

    (b)Address of Issuer’s Principal Executive Offices:

     

    305 College Road East

    Princeton, New Jersey 08540

     

    Item 2.(a) Name of Person Filing:

     

    Granahan Investment Management LLC

     

    (b)Address of Principal Business Office or, if None, Residence:

     

    Wyman Street, Suite 460

    Waltham, MA 02451

     

    (c)Citizenship:

     

    State of Massachusetts

     

    (d)Title of Class of Securities:

     

    Common Stock, par value $0.001

     

    (e)CUSIP Number:

     

    23283X206

     

    Item 3.If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

     

    (a)[  ] Broker or dealer registered under Section 15 of the Exchange Act.

     

    (b)[  ] Bank as defined in Section 3(a)(6) of the Exchange Act.

     

    (c)[  ] Insurance company as defined in Section 3(a)(19) of the Exchange Act.

     

    (d)[  ] Investment company registered under Section 8 of the Investment Company Act.

     

    (e[X] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

     

    (f)[  ] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

     

    (g)[  ] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

     

    (h)[  ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

    (i)[  ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

    (j)[  ] Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

     

     

     

    CUSIP NO. 23283X206 13G Page 4 of 5 Pages

     

    Item 4.Ownership.

     

      (a) Amount beneficially owned: 2,094,882
      (b) Percent of class: 3.85%
      (c) Number of shares as to which the person has:  
        (i) Sole power to vote or to direct the vote: 1,650,047
        (ii) Shared power to vote or to direct the vote: 0
        (iii) Sole power to dispose or to direct the disposition of: 2,094,882
        (iv) Shared power to dispose or to direct the disposition of: 0

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. [ ]

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    All of the Shares set forth in Item 4 are owned by various investment advisory clients of Granahan Investment Management LLC, which is deemed to be a beneficial owner of those shares pursuant to Rule 13d-3 under the Securities Exchange Act of 1934, due to its discretionary power to make investment decisions over such shares and/or its ability to vote such shares.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable

     

     

    CUSIP NO. 23283X206 13G Page 5 of 5 Pages

     

    Item 10.Certification.

     

    By signing below the undersigned certifies that, to the best of my knowledge and belief, the securities referred to above were acquired and held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      Granahan Investment Management LLC  
           
      By:

    /s/Brian Granahan

     
      Name: Brian Granahan  
      Title: Chief Compliance Officer  
           
      Date: November 14, 2024  

     

     

     

    Get the next $CTSO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CTSO

    DatePrice TargetRatingAnalyst
    9/7/2023$4.00Buy
    B. Riley Securities
    10/14/2021$10.00Buy
    B. Riley Securities
    More analyst ratings

    $CTSO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Bator Michael G. increased direct ownership by 7% to 151,273 units (SEC Form 4)

      4 - Cytosorbents Corp (0001175151) (Issuer)

      3/4/25 9:00:21 PM ET
      $CTSO
      Medical/Dental Instruments
      Health Care
    • President and COO Capponi Vincent increased direct ownership by 2% to 677,168 units (SEC Form 4)

      4 - Cytosorbents Corp (0001175151) (Issuer)

      2/26/25 7:29:54 PM ET
      $CTSO
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Mariani Peter J increased direct ownership by 8% to 466,613 units (SEC Form 4)

      4 - Cytosorbents Corp (0001175151) (Issuer)

      2/26/25 7:28:35 PM ET
      $CTSO
      Medical/Dental Instruments
      Health Care

    $CTSO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Mariani Peter J bought $19,294 worth of shares (20,000 units at $0.96), increasing direct ownership by 5% to 401,363 units (SEC Form 4)

      4 - Cytosorbents Corp (0001175151) (Issuer)

      12/16/24 7:00:11 AM ET
      $CTSO
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Mariani Peter J bought $27,975 worth of shares (31,363 units at $0.89), increasing direct ownership by 9% to 381,363 units (SEC Form 4)

      4 - Cytosorbents Corp (0001175151) (Issuer)

      12/13/24 8:00:13 AM ET
      $CTSO
      Medical/Dental Instruments
      Health Care
    • Sobel Alan D. bought $30,001 worth of shares (22,557 units at $1.33), increasing direct ownership by 28% to 101,857 units (SEC Form 4)

      4 - Cytosorbents Corp (0001175151) (Issuer)

      12/15/23 4:35:14 PM ET
      $CTSO
      Medical/Dental Instruments
      Health Care

    $CTSO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CytoSorbents Reports First Quarter 2025 Financial Results and Provides Business Update

      PRINCETON, N.J., May 14, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported financial results for the first quarter ended March 31, 2025, and recent business highlights.  CTSO) is a leader in the treatment of life-threatening conditions using blood purification. CytoSorbents' flagship product, CytoSorb®, is approved in the European Union and distributed in over 70 countries worldwide. CytoSorbents is conducting trials to support FDA marketing approval of DrugSorb™-ATR for

      5/14/25 4:01:00 PM ET
      $CTSO
      Medical/Dental Instruments
      Health Care
    • CytoSorbents Provides Regulatory Update for DrugSorb-ATR

      PRINCETON, N.J., May 1, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in blood purification therapies for life-threatening conditions in the intensive care unit and cardiac surgery, today provided a regulatory update for DrugSorb™-ATR, its FDA-designated Breakthrough Device.  DrugSorb-ATR is designed to reduce the severity of bleeding in patients undergoing coronary artery bypass grafting (CABG) surgery within 2 days of stopping the antiplatelet drug Brilinta® (ticagrelor, AstraZeneca), a commonly used blood thinner. CTSO) is a leader in the treatment of life-threatening conditions using blood purific

      5/1/25 4:15:00 PM ET
      $CTSO
      Medical/Dental Instruments
      Health Care
    • CytoSorbents to Report First Quarter 2025 Financial Results and Recent Business Highlights

      PRINCETON, N.J., April 29, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report first quarter 2025 financial results and recent business highlights after the market close on Wednesday, May 14, 2025. CTSO) is a leader in the treatment of life-threatening conditions using blood purification. CytoSorbents' flagship product, CytoSorb®, is approved in the European Union and distributed in over 70 countries worldwide. CytoSorbents is conducting trials to support FDA marketing approv

      4/29/25 7:00:00 AM ET
      $CTSO
      Medical/Dental Instruments
      Health Care

    $CTSO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Cytosorbents Corporation

      SC 13G/A - Cytosorbents Corp (0001175151) (Subject)

      11/14/24 4:48:32 PM ET
      $CTSO
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Cytosorbents Corporation

      SC 13G - Cytosorbents Corp (0001175151) (Subject)

      2/14/24 4:42:32 PM ET
      $CTSO
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Cytosorbents Corporation

      SC 13G - Cytosorbents Corp (0001175151) (Subject)

      2/14/24 9:00:04 AM ET
      $CTSO
      Medical/Dental Instruments
      Health Care

    $CTSO
    Financials

    Live finance-specific insights

    See more
    • CytoSorbents Reports First Quarter 2025 Financial Results and Provides Business Update

      PRINCETON, N.J., May 14, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported financial results for the first quarter ended March 31, 2025, and recent business highlights.  CTSO) is a leader in the treatment of life-threatening conditions using blood purification. CytoSorbents' flagship product, CytoSorb®, is approved in the European Union and distributed in over 70 countries worldwide. CytoSorbents is conducting trials to support FDA marketing approval of DrugSorb™-ATR for

      5/14/25 4:01:00 PM ET
      $CTSO
      Medical/Dental Instruments
      Health Care
    • CytoSorbents to Report First Quarter 2025 Financial Results and Recent Business Highlights

      PRINCETON, N.J., April 29, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report first quarter 2025 financial results and recent business highlights after the market close on Wednesday, May 14, 2025. CTSO) is a leader in the treatment of life-threatening conditions using blood purification. CytoSorbents' flagship product, CytoSorb®, is approved in the European Union and distributed in over 70 countries worldwide. CytoSorbents is conducting trials to support FDA marketing approv

      4/29/25 7:00:00 AM ET
      $CTSO
      Medical/Dental Instruments
      Health Care
    • CytoSorbents Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

      2024 marked by strong commercial execution and improved operating leverageCompany continues to expect DrugSorb-ATR regulatory decisions from Health Canada and US FDA in 2025 Successful Rights Offering and exercise of Series A Right Warrants strengthens balance sheetStrengthening of clinical portfolio across cardiac surgery and critical care in 2025 with new presentations and publications The Company has now adopted the standard accounting convention of reporting Revenue to only include Product Sales. Grant Income is no longer reported as a component of RevenuePRINCETON, N.J., March 31, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening

      3/31/25 4:15:00 PM ET
      $CTSO
      Medical/Dental Instruments
      Health Care

    $CTSO
    Leadership Updates

    Live Leadership Updates

    See more
    • CytoSorbents Appoints Melanie Grossman, CPA as Vice President and Corporate Controller

      Ms. Grossman brings 25 years of accomplished finance and accounting experience in global, publicly-traded companies Company announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PRINCETON, N.J., April 17, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced the appointment of Melanie Grossman, CPA as Vice President and Corporate Controller.  Ms. Grossman joins CytoSorbents with over 25 years of accomplished finance and accounting experience in global, publicly-traded companies. 

      4/17/25 7:00:00 AM ET
      $CTSO
      Medical/Dental Instruments
      Health Care
    • CytoSorbents Appoints Thomas Shannon as Vice President of Marketing for North America

      PRINCETON, N.J., April 14, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced the appointment of Thomas Shannon as Vice President of Marketing for North America. With anticipated marketing approval, Mr. Shannon will lead the marketing strategy and execution for DrugSorb™-ATR in the U.S. and Canada. CTSO) is a leader in the treatment of life-threatening conditions using blood purification. CytoSorbents' flagship product, CytoSorb®, is approved in the European Union and di

      4/14/25 7:00:00 AM ET
      $CTSO
      Medical/Dental Instruments
      Health Care
    • CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India

      PRINCETON, N.J. and HYDERABAD, India, Nov. 11, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit (ICU) and during cardiac surgery through blood purification, and Converge Biotech, a prominent healthcare company with a strong critical care and infectious disease focus in India, are pleased to announce a new strategic collaboration where the two companies seek to expand their combined market reach in the sepsis and critical care markets in India with a broad synergistic product portfolio. CytoSorbents is renowned for its flagship product, CytoSorb®, a blood purification technology that red

      11/11/24 7:30:00 AM ET
      $CTSO
      Medical/Dental Instruments
      Health Care

    $CTSO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • B. Riley Securities initiated coverage on CytoSorbents with a new price target

      B. Riley Securities initiated coverage of CytoSorbents with a rating of Buy and set a new price target of $4.00

      9/7/23 8:13:32 AM ET
      $CTSO
      Medical/Dental Instruments
      Health Care
    • B. Riley Securities resumed coverage on CytoSorbents with a new price target

      B. Riley Securities resumed coverage of CytoSorbents with a rating of Buy and set a new price target of $10.00

      10/14/21 7:58:45 AM ET
      $CTSO
      Medical/Dental Instruments
      Health Care

    $CTSO
    SEC Filings

    See more
    • SEC Form 10-Q filed by Cytosorbents Corporation

      10-Q - Cytosorbents Corp (0001175151) (Filer)

      5/14/25 4:14:58 PM ET
      $CTSO
      Medical/Dental Instruments
      Health Care
    • Cytosorbents Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Cytosorbents Corp (0001175151) (Filer)

      5/14/25 4:11:54 PM ET
      $CTSO
      Medical/Dental Instruments
      Health Care
    • Cytosorbents Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Cytosorbents Corp (0001175151) (Filer)

      5/1/25 4:25:40 PM ET
      $CTSO
      Medical/Dental Instruments
      Health Care